首页> 外文期刊>Journal of clinical laboratory analysis. >Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer‐associated malignant pleural effusion
【24h】

Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer‐associated malignant pleural effusion

机译:联合检测胸腔液中胸腺,胸膜液腺苷脱氨基酶和胸腔流体碳水化合物抗原125临床价值在鉴定Nonsmall细胞肺癌相关恶性胸腔积液中的鉴定

获取原文
获取原文并翻译 | 示例
       

摘要

Background Midkine ( MK ) level has been shown to be elevated in serum of patients with nonsmall cell lung cancer ( NSCLC ). However, the diagnostic value of MK in pleural effusion in NSCLC has not been well validated and established. Methods Samples of NSCLC ‐associated malignant pleural effusions ( MPE ) and benign effusions ( BPE ) were collected. The pleural fluid MK ( pMK ), pleural fluid adenosine deaminase ( pADA ), pleural fluid lactate dehydrogenase ( pLDH ), pleural fluid glucose ( pGLU ), pleural fluid ferritin ( pFER ), pleural fluid CA 199 ( pCA 199), pleural fluid CA 125 ( pCA 125), pleural effusion white cell count ( pWBC ), and pleural effusion red cell count ( pRBC ) were analyzed, and the clinical data of each group were collected for statistical analysis. Result The level of pMK , pCA 125, pMK ?+? pCA 125, and pMK ?+? pCA 125?+? pADA in the MPE was significantly higher than the BPE group ( P ?=?.003, .000, .000, .000). The pADA level in the BPE was significantly higher than the MPE group ( P ?=?.003). It showed that the area under the ROC curve ( AUC ) (0.816) of jointly detection pMK , pCA 125, and pADA was significantly higher than other markers for the diagnosis of MPE . Therefore, joint detection of pMK ?+? pCA 125?+? pADA suggested that the sensitivity, specificity, and AUC was 82.54%, 74.19% at the cutoff 0.47 and diagnostic performance was higher than others. Conclusion Joint detection of pMK ?+? pCA 125?+? pADA can be used as a good indicator for the identification of MPE of NSCLC.
机译:背景技术米隆(MK)水平已显示在非球体细胞肺癌(NSCLC)的患者血清中升高。然而,MK在NSCLC中胸腔积液中的MK诊断值尚未得到很好的验证和建立。方法收集NSCLC -Asocational的恶性胸腔积液(MPE)和良性生效(BPE)的样品。胸腔液体MK(PMK),胸膜流体腺苷脱氨基酶(PADA),胸膜液乳酸脱氢酶(PLDH),胸腔流体葡萄糖(PGLU),胸腔液铁蛋白(PFER),胸腔流体CA 199(PCA 199),胸腔液CA分析了125(PCA 125),胸腔积液白细胞计数(PWBC)和胸腔积液红细胞计数(PRBC),收集每组的临床数据进行统计分析。结果PMK水平,PCA 125,PMK?+? PCA 125和PMK?+? PCA 125?+? MPE中的PADA显着高于BPE组(P?= 003,.000,.000,.000)。 BPE中的PADA水平显着高于MPE组(P?=→003)。它表明,ROC曲线(AUC)(AUC)(0.816)下的区域的共同检测PMK,PCA 125和PADA显着高于其他标志物,用于诊断MPE。因此,关节检测PMK?+? PCA 125?+? PADA表明,截止值为0.47的敏感性,特异性和AUC为82.54%,74.19%,诊断性能高于其他。结论PMK的关节检测?+? PCA 125?+? PADA可作为识别NSCLC的MPE的良好指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号